Subscribe to our Newsletters !!
Infections pose an everpresent threat to society a
Biotech Fluidics has introduced a durable dual sta
A new COVID-19 variant, BA.3.2, informally called
The sustained tensions between Iran and the United
For a number of years now, healthcare systems glob
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
New Delhi, Jan 6 (PTI) Homegrown pharma major Lupin Ltd on Wednesday said it has received approval from the US health regulator to market its generic version of sulfamethoxazole and trimethoprim oral suspension used in the treatment of bacterial infections.
Sulfamethoxazole and trimethoprim oral suspension, 200 mg/40 mg per 5 mL, is indicated for the treatment and prevention of a wide variety of bacterial infections (for example, middle ear, urine, respiratory, and intestinal infections), and certain sort of pneumonia (pneumocystis-type).
Citing IQVIA MAT September 2020 data, the company said the sulfamethoxazole and trimethoprimoral suspension had estimated annual sales of about USD 19 million in the usa. PTI RKL MKJ
